IRulya Therapeutics Inc.

US$31.00As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:IRLAHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (49.67%)
Div yield —
ROE (153.84%)
Biotechnology
Beta (5Y) 1.79
PE TTM —
TSR TTM (90.61%)
Mkt cap US$31.53M
ROIC (55.19%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$37
19.58%
(54.15%)
Hold 0|1|6|6|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.33
0.33
0.34
0.33
1.45%
4.62%
8.26%
4.64%
Revenue$M
1.538
1.615
1.631
1.640
8.10%
8.55%
9.22%
7.03%
Peers (US$31.53M)
Cap (US$)
PE
32.83M
—
31.04M
—
31.51M
—
Capital
TTM
5Y
10Y
Leveragex
1.026
0.714
0.532
EBIT/Intx
1.022
0.137
0.138
Own earn%
(170.32)
(24.16)
17.11
Sh yield%
47.91
23.28
24.04
Owners
Insiders/Inst%
0.23
40.18
Short interest%
4.88
SBC / revenue%
0.99
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
2–11
$1 testx
0.5
Incr. ROIC%
2